Aprea Therapeutics APRE Stock
Aprea Therapeutics Price Chart
Aprea Therapeutics APRE Financial and Trading Overview
| Aprea Therapeutics stock price | 0.83 USD |
| Previous Close | 0.72 USD |
| Open | 0.81 USD |
| Bid | 0.75 USD x 400 |
| Ask | 0.86 USD x 200 |
| Day's Range | 0.72 - 0.84 USD |
| 52 Week Range | 0.55 - 2.22 USD |
| Volume | 373.02K USD |
| Avg. Volume | 382.69K USD |
| Market Cap | 9.83M USD |
| Beta (5Y Monthly) | 1.558 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.49 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.3 USD |
APRE Valuation Measures
| Enterprise Value | -35911868 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.004557 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 79.70227 |
| Price/Book (mrq) | 0.2286373 |
| Enterprise Value/Revenue | -291.265 |
| Enterprise Value/EBITDA | 2.86 |
Trading Information
Aprea Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.558 |
| 52-Week Change | -51.43% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 2.22 USD |
| 52 Week Low | 0.55 USD |
| 50-Day Moving Average | 0.85 USD |
| 200-Day Moving Average | 1.01 USD |
APRE Share Statistics
| Avg. Volume (3 month) | 382.69K USD |
| Avg. Daily Volume (10-Days) | 136.16K USD |
| Shares Outstanding | 12.38M |
| Float | 7.42M |
| Short Ratio | 0.62 |
| % Held by Insiders | 11.55% |
| % Held by Institutions | 18.12% |
| Shares Short | 119.01K |
| Short % of Float | 1.01% |
| Short % of Shares Outstanding | 0.95% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10202.0064% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.17% |
| Return on Equity (ttm) | -40.40% |
Income Statement
| Revenue (ttm) | 123.3K USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -6047840 USD |
| EBITDA | -12556952 USD |
| Net Income Avi to Common (ttm) | -11954827 USD |
| Diluted EPS (ttm) | -1.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 46.47M USD |
| Total Cash Per Share (mrq) | 3.75 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 8.92 |
| Book Value Per Share (mrq) | 3.471 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12020002 USD |
| Levered Free Cash Flow (ttm) | -5625328 USD |
Profile of Aprea Therapeutics
| Country | United States |
| State | PA |
| City | Doylestown |
| Address | 3805 Old Easton Road |
| ZIP | 18902 |
| Phone | 215 948 4119 |
| Website | https://aprea.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Q&A For Aprea Therapeutics Stock
What is a current APRE stock price?
Aprea Therapeutics APRE stock price today per share is 0.83 USD.
How to purchase Aprea Therapeutics stock?
You can buy APRE shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aprea Therapeutics?
The stock symbol or ticker of Aprea Therapeutics is APRE.
Which industry does the Aprea Therapeutics company belong to?
The Aprea Therapeutics industry is Biotechnology.
How many shares does Aprea Therapeutics have in circulation?
The max supply of Aprea Therapeutics shares is 12.38M.
What is Aprea Therapeutics Price to Earnings Ratio (PE Ratio)?
Aprea Therapeutics PE Ratio is now.
What was Aprea Therapeutics earnings per share over the trailing 12 months (TTM)?
Aprea Therapeutics EPS is -1.49 USD over the trailing 12 months.
Which sector does the Aprea Therapeutics company belong to?
The Aprea Therapeutics sector is Healthcare.
Aprea Therapeutics APRE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}